Chris Markoch

Chris Markoch

InvestorPlace Contributor

Chris Markoch is a freelance financial writer who brings over 25 years in sales and marketing to help find the story behind the stock. Chris starts by asking the question, “So what?” and then uses fundamental and (some) technical analysis to add depth to that insight.

Stepping back from the “what” allows Chris to bring perspective that helps investors make wise decisions based on their risk tolerance and investing timeline.

Markoch would describe his writing as being for investors more than traders. He looks at equities through a long-term lens and that is reflected in his writing.

In addition to his articles on InvestorPlace, you can also find Chris’ writing on MarketBeat.com where he has collaborated on the e-book “5 Investing Trends That Will Define the Market in 2022.” You can find Chris on LinkedIn and on Twitter.

Recent Articles

SPCE Stock May Not Fail to Launch, But It May Still Fail

By Chris Markoch, InvestorPlace Contributor

Virgin Galactic is close to generating revenue. But with the owner selling SPCE stock to shore up his virus-infected businesses, failure is still an option.

Could Southwest Airlines Be Ready for a Rebound?

By Chris Markoch, InvestorPlace Contributor

With evidence that travelers are gradually warming to the idea of flying, this may be the time to consider a speculative bet on LUV stock.

7 Tech Stocks That Are Bolstered by Contact Tracing Initiatives

By Chris Markoch, InvestorPlace Contributor

Many countries are using contact tracing to mitigate the spread of Covid-19 in a pre-vaccine world. These tech stocks are leading the way.

Does One Earnings Report Make Aurora Cannabis Lucky or Good?

By Chris Markoch, InvestorPlace Contributor

On the surface, Aurora Cannabis' earnings report demonstrated progress, which lifted ACB stock. However, the fine print leaves much to be desired.

Humana Stock Faces a Paradox That Will Determine Its Short-Term Growth

By Chris Markoch, InvestorPlace Contributor

The bullish case for HUM stock centers on patients rescheduling elective procedures in the coming months. But what if that doesn't happen?

AbbVie Is More Than Just a Portfolio of Drugs and Acquisitions

By Chris Markoch, InvestorPlace Contributor

With AbbVie's buyout of Allergan officially finalized, ABBV stock has moved significantly higher since then. However, ABBV is so much more than this headline event.

Visa’s Fortunes Are Tied to a Tenuous Jobs Market

By Chris Markoch, InvestorPlace Contributor

Consumer spending has shifted, but may slow down even more if the United States has a jobless recovery, raising skepticism toward V stock.

Fair Warning: The Clock Is Ticking on Netflix Stock Growth

By Chris Markoch, InvestorPlace Contributor

NFLX stock is up nearly 50% during the Covid-19 pandemic. But with the CEO warning of slower growth, is the stock still a buy?

When the Virus Fog Lifts, Will Delta Air Lines Stock Be Flying Again?

By Chris Markoch, InvestorPlace Contributor

It may be tempting to take a chance on Delta. But while DAL stock may be near a bottom, growth looks to be many years away.

Investors Should Socially Distance From Lyft Stock

By Chris Markoch, InvestorPlace Contributor

The worst is yet to come for Lyft stock. As the economy re-opens, there is reason to believe Lyft's customers may not return.

Load More